Dexilant SoluTab Approval History
- FDA approved: Yes (First approved January 26th, 2016)
- Brand name: Dexilant SoluTab
- Generic name: dexlansoprazole
- Dosage form: Delayed-Release Orally Disintegrating Tablets
- Company: Takeda Pharmaceuticals U.S.A., Inc.
- Treatment for: GERD
Dexilant SoluTab (dexlansoprazole) is a proton pump inhibitor (PPI) indicated for the treatment of patients with heartburn associated with gastroesophageal reflux disease (GERD).
Dexilant was first approved in capsule form in 2009. Dexilant SoluTab is a new formulation of dexlansoprazole that can be taken by allowing the tablet to melt in the mouth. The tablets may also be swallowed whole with water.
The recommended adult dosage for Dexilant SoluTab is one 30 mg tablet taken once daily at least 30 minutes before a meal. The tablets should be placed on the tongue, and allowed to disintegrate (melt). The remaining microgranules should be swallowed without water and should not be chewed.
The most commonly reported side effects include diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence. Patients should avoid alcohol during treatment with Dexilant SoluTab.
Development History and FDA Approval Process for Dexilant SoluTab
|Jan 27, 2016||FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole)|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.